Revelation Biosciences (REVB) director granted 41,981 RSUs at $0.90

Rhea-AI Filing Summary

Revelation Biosciences director Lakhmir S. Chawla reported an equity grant. On January 8, 2026, he acquired 41,981 shares of common stock at $0.90 per share, reported as an award under transaction code “A.” After this grant, he beneficially owned 57,667 shares of Revelation Biosciences common stock held directly.

The award represents a restricted stock unit grant under the 2021 Equity Incentive Plan, which vests quarterly over one year from the grant date. The filing reflects his status as a director of Revelation Biosciences, Inc. (ticker REVB) and indicates this was a Form 4 filed for a single reporting person.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chawla Lakhmir S

(Last) (First) (Middle)

4660 LA JOLLA VILLAGE DR

SUITE 100

(Street)

SAN DIEGO CA 92122

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
REVELATION BIOSCIENCES, INC. [ REVB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								15,686	D
Common Stock(1)	01/08/2026		A		41,981	A	$0.9	57,667	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted Stock Unit under the 2021 Equity Incentive Plan. Vests quarterly over one year from the date of grant.

	/s/ J.P. Galda, as attorney-in-fact for Lakhmir S Chawla	01/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did REVB director Lakhmir S. Chawla report?

Director Lakhmir S. Chawla reported an award of 41,981 shares of Revelation Biosciences common stock on January 8, 2026, coded as an acquisition ("A").

How many Revelation Biosciences (REVB) shares does the director own after this Form 4?

Following the reported transaction, Lakhmir S. Chawla beneficially owned 57,667 shares of Revelation Biosciences common stock, held directly.

What was the price per share for the REVB equity grant reported?

The reported equity grant was valued at $0.90 per share for the 41,981 shares of common stock acquired on January 8, 2026.

What type of equity award did the Revelation Biosciences director receive?

The director received a restricted stock unit (RSU) grant under the 2021 Equity Incentive Plan, as noted in the explanation of responses.

How do the RSUs granted to the REVB director vest?

The filing states that the restricted stock units vest quarterly over one year from the date of grant.

Is this Revelation Biosciences Form 4 filed for more than one reporting person?

No. The document indicates that the Form 4 was filed by one reporting person, director Lakhmir S. Chawla.